Document is current

Article History

Received: 11 June 2018

Accepted: 7 December 2018

First Online: 22 January 2019

Authors’ information

: Gemma Taylor is an Assistant Professor in Clinical Psychology and the University of Bath, United Kingdom; Paul Aveyard is a Professor of Behavioural Medicine at the University of Oxford; Kate Bartlem is a Research Fellow at, the University of Newcastle, Australia; Ali Shaw is a Senior Research Fellow at the University of Bristol; Jeremy Player is a Project Support Officer at Solutions4Health; Chris Metcalfe is a Professor of Medical Statistics at the University of Bristol; David Kessler is a Reader in Primary Care at the University of Bristol; Marcus Munafò is a Professor of Biological Psychology at the University of Bristol.

: This study received ethics approval from the National Health Service Research Ethics Committee on 19/03/2018 (IRAS ID: 239339). Contact details for sponsor: Dr Lisa Austin, University of Bath, Bath, United Kingdom, l.austin@bath.ac.uk.

: Not applicable.

: Drs. Ali Shaw, David Kessler and Kate Bartlem have no conflicts of interest. Professor Chris Metcalfe has no conflicts of interest. Dr Gemma Taylor and Professor Marcus Munafò have received funding from Pfizer, who manufacture smoking cessation products. Professor Paul Aveyard led a trial funded by the NIHR and Glaxo Smith Kline donated nicotine patches to the NHS in support of the trial.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.